Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1606)	1/14/2008 4:07:12 PM
From: tuck	Respond to of 1834

Lyons outta here (though will be on the BOD): >>Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer Monday January 14, 4:01 pm ET SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) announced today that Kevin Gorman, Ph.D., Neurocrine's Chief Operating Officer has been appointed President and Chief Executive Officer and a member of the Board of Directors of Neurocrine Biosciences. Gary Lyons will step down as President and Chief Executive Officer of Neurocrine and will continue to serve as a member of the Board of Directors. "While this was a very difficult decision for me, I believe the time is right for a change in leadership of Neurocrine. With three Phase II products, $180 million in cash and an extremely talented and experienced management team and dedicated staff, Neurocrine is well positioned to emerge as one of the leading biotechnology companies under Kevin's leadership," said Gary Lyons. "The Board is indebted to Gary for his dedication and service over the past 14 years and we are grateful that he will continue to share his knowledge and expertise as a Board member as he transitions his responsibilities to Kevin," said Joe Mollica, Chairman of the Board. "Dr. Gorman has been an integral part of Neurocrine since its founding and has played key roles in the company's success over the years. We look forward to working with Kevin in his new leadership capacity in setting the strategy and direction of the company going forward." Dr. Gorman, 50, was appointed Chief Operating Officer in September 2006 after having served as Executive Vice President and Chief Business Officer of Neurocrine Biosciences. In this position Dr. Gorman was responsible for R&D, Business Development and Commercial operations. Before joining Neurocrine in 1993, Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of Neurocrine and several other biotechnology companies such as Onyx Pharmaceuticals, Metra Biosystems, IDUN and ARIAD Pharmaceuticals. Dr. Gorman received his Ph.D. in Immunology from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University. Dr. Gorman also received his M.B.A. in Finance from the Anderson Graduate School of Management.<< snip Don't see much reaction in share price after hours, but maybe it's too soon for the market to figure out what it thinks. Cheers, Tuck